MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2021.05.027

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2021

Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.

Marmé Frederik, Solbach Christine, Michel Laura, Schneeweiss Andreas, Blohmer Jens-Uwe, Huober Jens, Fasching Peter A, Jackisch Christian, Nekljudova Valentina, Link Theresa, Rhiem Kerstin, Rey Julia, Denkert Carsten, Hanusch Claus, Tesch Hans, Lederer Bianca, Loibl Sibylle, Untch Michael

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with superior survival. This association is strongest in triple-negative breast cancer (TNBC). The CPS + EG system, based on pre-treatment clinical (CS) and post-treatment pathological stage (PS), oestrogen-receptor status (E) and grade (G), leads to a refined estimate of prognosis after NACT in all-comers and hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here, we investigate if CPS + EG scoring provides a superior estimate of prognosis in TNBC to select patients for postneoadjuvant therapy.

METHODS

We calculated the CPS + EG score for 1795 patients with TNBC from 8 prospective German trials. Five-year disease-free survival (DFS) and overall survival estimates were calculated using the Kaplan-Meier method.

RESULTS

In TNBC, patients with pCR (ypT0/is ypN0, n = 822, 45.8%) had a 5-year DFS of 86%, whereas patients with residual American Joint Committee on Cancer stage I disease (n = 383; 21.3%) had a 5-year DFS of 77.5%.CPS + EG led to superior prognostic information compared with that provided by the clinical stage, but it was inferior to the prognostic information provided by the pathological stage (c-index statistics, p < 0.001). CPS + EG did not discriminate prognosis within the two best prognostic groups (score 1 and 2; n = 362; 37.2%). In contrast, pCR status added prognostic information beyond CPS + EG. Patients with a CPS + EG score of 3 had a 5-year DFS rate of 64% overall, but those with pCR had a 5-year DFS rate of 84%, and those without pCR had a 5-year DFS rate of only 49.7%.

CONCLUSIONS

In TNBC, CPS + EG scoring provided inferior prognostic information compared with the pathological stage and was unable to identify patients without pCR and with a sufficiently good prognosis, who could avoid postneoadjuvant therapy. pCR remains the strongest and most clinically useful prognostic factor after NACT. Other biologic factors beyond pCR are needed in TNBC.

Для цитирования: Marmé Frederik, Solbach Christine, Michel Laura, Schneeweiss Andreas, Blohmer Jens-Uwe, Huober Jens, Fasching Peter A, Jackisch Christian, Nekljudova Valentina, Link Theresa, Rhiem Kerstin, Rey Julia, Denkert Carsten, Hanusch Claus, Tesch Hans, Lederer Bianca, Loibl Sibylle, Untch Michael. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.. European journal of cancer (Oxford, England : 1990). 2021. DOI: 10.1016/j.ejca.2021.05.027.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.